Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs ONC

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:ONC)

Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

Business Wire November 5, 2019

BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of Stockholders and Encourages Investors to Contact the Firm

Business Wire November 1, 2019

BeiGene Announces Global Strategic Oncology Collaboration with Amgen

GlobeNewswire October 31, 2019

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud: Investors Who Suffered Losses Encouraged to Contact Firm

GlobeNewswire October 29, 2019

ROSEN, A HIGHLY RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

Business Wire October 28, 2019

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA October 23, 2019

ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

GlobeNewswire October 18, 2019

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA October 18, 2019

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA October 16, 2019

Lifshitz & Miller LLP Announces Investigation of Aflac Inc., BeiGene, Ltd., Meredith Corporation, New Relic, Inc., Ollie's Bargain Outlet Holdings, Inc., SmileDirectClub, Inc., and Sonim Technologies, Inc.

PR Newswire October 8, 2019

BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud

GlobeNewswire October 7, 2019

ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

GlobeNewswire October 7, 2019

Bragar Eagel & Squire, P.C. Is Investigating Tandy Leather Factory, ADTRAN, BeiGene, and Altria Group on Behalf of Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire October 1, 2019

BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud

GlobeNewswire September 30, 2019

BGNE LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

GlobeNewswire September 30, 2019

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019

GlobeNewswire September 30, 2019

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019

GlobeNewswire September 26, 2019

BGNE LOSSES ALERT: Bernstein Liebhard LLP Shareholders of its Investigation of BeiGene Ltd.

PR Newswire September 25, 2019

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against BeiGene, Ltd. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire September 25, 2019

BGNE INVESTIGATION REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud

GlobeNewswire September 23, 2019